Home > Boards > US Listed > Medical - Drugs > Phio Pharmaceuticals Corp (PHIO)

PR Newswire March 31, 2020, 6:30 am Animal studies show

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Beano1969 Member Profile
 
Followed By 31
Posts 2,787
Boards Moderated 0
Alias Born 02/12/17
160x600 placeholder
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 7/20/2020 5:15:57 PM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 7/20/2020 6:02:45 AM
Securities Registration Statement (s-1) Edgar (US Regulatory) - 7/9/2020 5:21:21 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 6/2/2020 5:01:34 PM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 6/2/2020 6:00:53 AM
Securities Registration Statement (s-1/a) Edgar (US Regulatory) - 5/28/2020 5:17:11 PM
Securities Registration Statement (s-1) Edgar (US Regulatory) - 5/12/2020 5:11:56 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/12/2020 4:37:03 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/12/2020 4:36:57 PM
Small Company Offering and Sale of Securities Without Registration (d) Edgar (US Regulatory) - 4/14/2020 5:17:21 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 4/9/2020 10:13:32 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 4/8/2020 4:43:36 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/2/2020 5:01:32 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 4/1/2020 5:02:20 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/26/2020 5:27:41 PM
Annual Report (10-k) Edgar (US Regulatory) - 3/26/2020 5:26:39 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/12/2020 4:16:10 PM
Small Company Offering and Sale of Securities Without Registration (d) Edgar (US Regulatory) - 2/24/2020 5:28:22 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/14/2020 2:52:49 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/13/2020 5:27:09 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/13/2020 5:25:17 PM
Prospectus Filed Pursuant to Rule 424(b)(4) (424b4) Edgar (US Regulatory) - 2/12/2020 5:22:26 PM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 2/12/2020 6:01:05 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/11/2020 1:04:53 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/10/2020 3:19:17 PM
Beano1969   Tuesday, 03/31/20 07:47:20 AM
Re: None
Post # of 4898 
PR Newswire
March 31, 2020, 6:30 am
Animal studies show a complete and statistically significant (p <0.0001) inhibition of tumor growth

MARLBOROUGH, Mass., March 31, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYLâ„¢) therapeutic platform, today announced data from various animal studies validating the potential of Phio's INTASYL technology as a cancer immunotherapy platform for developing novel compounds. The preclinical findings, which will be presented in further detail at upcoming scientific conferences, demonstrate that the INTASYL-enabled compounds can effectively be used to reduce immunosuppression in the tumor microenvironment (TME), which is one of the key challenges for many other immunotherapy platforms to achieve an adequate therapeutic effect in solid tumors.


https://www.google.com/amp/s/finance.yahoo.com/amphtml/news/phio-announces-positive-data-validating-113000532.html

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist